deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT04676724

Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB) (B-Together)

A Phase IIb Multi-Center, Randomised, Open Label Study to Assess the Efficacy and Safety of Sequential Treatment With GSK3228836 Followed by Pegylated Interferon Alpha 2a in Participants With Chronic Hepatitis B Virus (B-Together)

Sponsor: GlaxoSmithKline

Conditions Hepatitis B
Interventions GSK3228836 NA therapy PegIFN
Updated 19 times since 2021 Last updated: Apr 8, 2024 Started: Jan 28, 2021 Primary completion: Feb 17, 2023 Completion: Feb 17, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Hepatitis B and is currently completed. GlaxoSmithKline leads this study, which shows 19 recorded versions since 2021 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Sep 2022 · 8 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Nov 2023 · 8 months · monthly snapshot~Nov 2023 – ~Jun 2024 · 7 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 9 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jun 2024 — Jul 2024 [monthly]

    Completed PHASE2

  5. Nov 2023 — Jun 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 14 earlier versions

  1. Mar 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE2

  2. Feb 2023 — Mar 2023 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2023 — Feb 2023 [monthly]

    Active Not Recruiting PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE2

  6. Jan 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  7. Dec 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE2

  8. Nov 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  9. Sep 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

  10. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  11. Apr 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  12. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  13. Feb 2021 — Mar 2021 [monthly]

    Not Yet Recruiting PHASE2

  14. Jan 2021 — Feb 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aichi, Japan , Baggiovara (MO), Italy , Barcelona, Spain , Barnaul, Russia , Beijing, China , Busan, South Korea , Calgary, Canada , Changchun, China , Chelyabinsk, Russia , Daegu, South Korea and 35 more locations